Ophthalmology Times

04/29/2026

Eyecelerator, in collaboration with Unither Pharmaceuticals and Ora, Inc., has launched Eye to Market, a web-based educational series designed to clarify how ophthalmic innovations progress from early scientific discovery to clinically validated, commercially viable therapies. The initiative targets a broad professional audience including clinicians, clinical investigators, innovators, and industry stakeholders and emphasizes the multidisciplinary coordination required to translate promising concepts into accessible patient care solutions.

New expert‑led series explores how ophthalmic innovations move from early development to market‑ready therapies through cross‑functional collaboration.

04/28/2026

The CONDOR randomized clinical trial (NCT04278417) showed both that brolucizumab (Beovu, Novartis) was superior to panretinal laser photocoagulation (PRP) for preserving visual acuity (VA) and that the drug may be a viable alternative therapy for treating patients with proliferative diabetic retinopathy (PDR).

PRP has been the long-standing treatment for PDR and severe nonproliferative DR. While the laser treatment efficacy is well-known, it is associated with potential complications, ie, choroidal effusions, exudative retinal detachments, macular edema, visual field deficits, and night vision defects, according to the investigators.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

04/27/2026

Alice Epitropoulos, MD, Director of the Dry Eye Center of Excellence, The Eye Center of Columbus, Columbus, OH, moderated a recent Ophthalmology Times case-based roundtable that focused on optimizing the ocular surface of patients scheduled for surgery.

Greater awareness of Demodex in surgical and dry eye patients.

04/26/2026

Ocular surface disease continues to expand as a focus of clinical care, with increasing attention to diagnosis, disease subtypes, and emerging therapies. Christopher E. Starr, MD, FACS, of Weill Cornell Medicine in New York City, emphasized that dry eye should be viewed within a broader framework, noting that ocular surface disease “is the term I like to use,” with dry eye representing only one component of a larger spectrum.

Christopher E. Starr, MD, FACS, highlights diagnostic gaps in dry eye, emphasizing neuropathic corneal pain and reviewing emerging therapies and pipeline treatments in ocular surface disease.

04/25/2026

Glaukos Corporation announced that the US Centers for Medicare and Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa HD / Epioxa for the treatment of keratoconus. The new code, J2789, is scheduled to take effect July 1, 2026, according to the company.

CMS assigns billing code to support reimbursement for the keratoconus therapy.

04/24/2026

Will you be in Fort Lauderdale, Florida, on May 15? We are hosting two events for retina specialists. Eligible professionals will receive $500 in compensation for their input. Learn more and join us!

Geographic Atrophy Case-Based Roundtable® with Priya Vakharia, MD: https://hubs.li/Q04dqh0w0
This session is catered towards residents, fellows, and retina specialists with under 10 years in practice.

Anti-VEGF Case-Based Roundtable® with Michael Ammar, MD: https://hubs.li/Q04dqbDG0
This discussion is for you if you are a retina specialist with over 10 years in practice.

Plus, invite a qualified colleague and earn a $50 referral bonus (up to 2) when you both attend and complete the post-event survey.

To be eligible for either session, you must be a practicing ophthalmologist in the US actively involved in treating patients with retinal diseases such as neovascular AMD, DME, or RVO.

Register now via the links above!

04/24/2026

Investigators from the Wilmer Eye Institute and the Bloomberg School of Public Health at Johns Hopkins University, both in Baltimore, reported in JAMA Ophthalmology that patients with dual sensory impairment (ie, hearing and vision) had a “reduced likelihood of functional improvement following vision rehabilitation.”

The investigators, led by first author Anas Obaideen, MBBS, MPH, suggest that interdisciplinary efforts in rehabilitation may better benefit patients with dual sensory impairment.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

04/23/2026

A large retrospective cohort study using the TriNetX electronic health records platform found that smoking is associated with an increased risk of multiple vision-threatening ocular conditions over a 10-year period. The analysis, led by first author Marina Gad El Sayed, a medical student at the University of California, Riverside, School of Medicine in Riverside, California, included 12,183,254 patients, with 304,823 identified as smokers and 11,878,431 as non-smokers.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

04/22/2026

Oculis Holding AG announced that the final patient visit has been completed in the DIAMOND phase 3 program assessing OCS-01, an investigational high-concentration dexamethasone eye drop, in patients with DME. Topline results from the 52-week trials are expected in June 2026, with a potential US regulatory submission anticipated later in the year. The absence of available data at this stage limits conclusions regarding clinical benefit or comparative effectiveness.

The company noted it expects topline results in June 2026.

04/20/2026

Atia Vision has presented positive 36-month results from its first-in-human study of the Atia Vision OmniVu Lens System.

Presented at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting by William Wiley, MD, medical director of the Cleveland Eye Clinic, these data reflect the modular shape-changing intraocular lens (IOL)’s capacity to restore a continuous and dynamic range of vision.

Data from a recent trial of the OmniVu Lens System was presented at ASCRS 2026, featuring positive and sustained vision endpoints.

04/19/2026

New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may offer extended durability and sustained anatomic control in patients with neovascular (wet) age-related macular degeneration (AMD), a finding that could have implications for treatment burden in this chronic disease.

The data, presented at the 14th Annual Vit-Buckle Society meeting, expand on previously reported topline results and include post hoc analyses evaluating central subfield thickness (CSFT) progression and visual outcomes. While the primary endpoint of the superiority trial—maintenance of visual acuity at week 36—has already been reported as positive, these additional analyses focus on durability metrics that are increasingly relevant in retina practice.

SOL-1 data show AXPAXLI extends wet AMD control, delaying fluid rebound and reducing rescue injections while sustaining vision through 52 weeks.